Status | Study |
NOT_YET_RECRUITING |
Study Name: Study of REM-422 in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma Condition: Adenoid Cystic Carcinoma Date: 2023-10-13 Interventions: REM-422 is a first in class, small molecule mRNA inhibitor that reduces expression of the MYB transcription factorREM-422 will be adm |
RECRUITING |
Study Name: CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC Condition: Adenoid Cystic Carcinoma Date: 2023-03-14 Interventions: First-in-class pan-NOTCH inhibitor, capsule taken orally. |
NOT_YET_RECRUITING |
Study Name: Drug Screening Using Novel IMD in ACC and Salivary Cancers Condition: Adenoid Cystic Carcinoma Date: 2022-09-19 Interventions: Percutaneous CT image-guided placement of the microdevice(s).At least one, and up to 3, devices will be placed in each tumor.Dr |
Not yet recruiting |
Study Name: Nivolumab and Ipilimumab in Treating Patients With Metastatic Recurrent Major or Minor Salivary Gland Cancer Condition: Major Salivary Gland Carcinoma Minor Salivary Gland Carcinoma Date: 2017-05-05 Interventions: Biological: Ipilimumab Given I |
Recruiting |
Study Name: Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma Condition: Adenoid Cystic Carcinoma Date: 2017-03-13 Interventions: Radiation: Radiation Standard |
Not yet recruiting |
Study Name: Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Condition: Adenoid Cystic Carcinoma Adnexal Carcinoma Date: 2016-11-30 Interventions: Other: Laboratory Biomarker Analysis |
Not yet recruiting |
Study Name: Trail Evaluating Particle Therapy With or Without Apatinib for H&N Adenoid Cystic Carcinoma Condition: Adenoid Cystic Carcinoma Date: 2016-10-18 Interventions: Drug: Apatinib Apatinib will b |
Not yet recruiting |
Study Name: Chidamide for Advanced Cephalic and Cervical Adenocystic Carcinoma: Evaluation of Efficiency and Safety Condition: Adenocystic Carcinoma Date: 2016-08-25 Interventions: Drug: Chidamide Other Name: epidaza |
Active, not recruiting |
Study Name: Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands: ACC-LEN14 Condition: Adenoid Cystic Carcinomas of the Salivary Glands Date: 2016-08-02 Interventions: Drug: Lenvatinib Lenvatinib will be self orally administered at 24 mg daily, on a continuous basis in 4 |
Recruiting |
Study Name: Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic Carcinoma Condition: Recurrent ACC, metastaticACC, Unreaectable ACC Date: 2016-07-28 Interventions: Drug: Axitinib Dosing schedule |